Searchable abstracts of presentations at key conferences in endocrinology

ea0026p682 | Diabetes therapy | ECE2011

The addition of acipimox in patients with type 2 diabetes with triglyceride level over 150 mg/dl in spite of fenofibrate therapy

Kim D-M , Park J R

Patients with type 2 diabetes have an increased risk of premature coronary heart disease (CHD). One of the underlying reasons for this increased risk is atherogenic dyslipidemia. Current management strategies focus on the initial use of statin or fibrate therapy (the latter approach indicated in patients with pronounced hypertriglyceridemia).American Diabetes Association recognizes serum triglycerides as a surrogate for atherogenic triglyceride-rich lipo...